Tirzepatide shifts 81.8-91.6% of obese patients to lower BMI categories, significantly improving cardiometabolic markers

Obesity is a chronic, multifactorial disease characterized by excess adiposity, significantly increasing the risk of all-cause mortality and comorbidities like hypertension, dyslipidemia, and cardiovascular diseases. Current guidelines recommend at least 5% weight loss, with greater benefits seen at ≥10%. However, achieving and sustaining such significant weight loss remains a major challenge with conventional treatments, highlighting a critical need for more effective pharmacological interventions that can induce substantial and durable weight reduction.

This was a post hoc analysis of data from two large randomized clinical trials, SURMOUNT-1 and SURMOUNT-4, involving participants with obesity or overweight. The study assessed cardiometabolic risk factors in individuals treated with tirzepatide who achieved a shift to a lower BMI category. Changes from baseline in fasting insulin and lipids were calculated using log transformation, while other parameters were reported as direct changes. The analysis compared participants who improved their BMI category against those who did not, focusing on the magnitude of weight loss and associated metabolic improvements.

A substantial proportion of participants treated with tirzepatide experienced an improvement in their BMI category from baseline: 81.8% in SURMOUNT-1 and 91.6% in SURMOUNT-4. Among these improvers, mean BMI reductions were significantly greater compared to those who did not improve their BMI category. In SURMOUNT-1, improvers saw a mean BMI reduction of -8.90 kg/m2 compared to -3.65 kg/m2 in non-improvers. For SURMOUNT-4, improvers achieved a mean BMI reduction of -10.47 kg/m2. These shifts were associated with significant improvements in cardiometabolic risk factors. >Participants who improved their BMI category demonstrated greater reductions in fasting insulin and improved lipid profiles, including beneficial changes in HDL-C, LDL-C, and VLDL-C, with most changes showing p<0.01 or p<0.001 significance.